Poolbeg Pharma plc

Directorate Change

30 November 2023 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change to its Board of Directors.

Patrick Ashe, Independent Non-Executive Director, will step down from the Board at the end of November. Patrick played a significant role in guiding the Company through its initial phase of development. Eddie Gibson, Non-Executive Director will replace Patrick as Chair of the Audit & Risk Committee and Prof Brendan Buckley, Non-Executive Director will become Chair of the Remuneration Committee.

Cathal Friel, Chairman of Poolbeg Pharma, commented: "We would like to thank Patrick for his contribution since joining at the IPO, where his knowledge and experience of growing biopharma companies has been of considerable value. Patrick joined the Company as part of its IPO and steps down from the Board at a time when Poolbeg is on an upward trajectory with a robust pipeline of high value programmes, and at a particularly exciting juncture following the recent appointment of three key former Amryt Pharma plc leadership members to the Poolbeg team with the view to replicating the success they had with Amryt. With a strong financial position, excellent clinical results achieved and productive partnering discussions ongoing, the Company is well positioned to generate significant shareholder value."

- Ends -

Enquiries

About Poolbeg Pharma

Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation.

Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.

Poolbeg's clinical programmes target large addressable markets across cancer immunotherapies, severe influenza, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.